Literature DB >> 16009695

When acquired thrombophilia mattered.

J S Hammond, L Jackson, A B Zaitoun, B J Rowlands, G P Aithal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16009695      PMCID： PMC1774885          DOI： 10.1136/gut.2005.069740

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

1.  Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli.

Authors:  M C Minnema; A C Chang; P M Jansen; Y T Lubbers; B M Pratt; B G Whittaker; F B Taylor; C E Hack; B Friedman
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

2.  DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.

Authors:  F B Taylor; A C Chang; G T Peer; T Mather; K Blick; R Catlett; M S Lockhart; C T Esmon
Journal:  Blood       Date:  1991-07-15       Impact factor: 22.113

3.  Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

Authors:  F Baudo; T M Caimi; F de Cataldo; A Ravizza; S Arlati; G Casella; D Carugo; G Palareti; C Legnani; L Ridolfi; R Rossi; A D'Angelo; L Crippa; D Giudici; G Gallioli; A Wolfler; G Calori
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

4.  The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity.

Authors:  C M Kessler; Z Tang; H M Jacobs; L M Szymanski
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

5.  Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha.

Authors:  M A Martínez; J M Peña; A Fernández; M Jiménez; S Juárez; R Madero; J J Vázquez
Journal:  Crit Care Med       Date:  1999-07       Impact factor: 7.598

6.  Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

Authors:  B Eisele; M Lamy; L G Thijs; H O Keinecke; H P Schuster; F R Matthias; F Fourrier; H Heinrichs; U Delvos
Journal:  Intensive Care Med       Date:  1998-07       Impact factor: 17.440

7.  Time course of hemostatic abnormalities in sepsis and its relation to outcome.

Authors:  J A Lorente; L J García-Frade; L Landín; R de Pablo; C Torrado; E Renes; A García-Avello
Journal:  Chest       Date:  1993-05       Impact factor: 9.410

8.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.

Authors:  F Fourrier; C Chopin; J Goudemand; S Hendrycx; C Caron; A Rime; A Marey; P Lestavel
Journal:  Chest       Date:  1992-03       Impact factor: 9.410
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.